Incontinence after Prostate Treatment: AUA/SUFU Guideline.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 7 5 2019
medline: 14 8 2019
entrez: 7 5 2019
Statut: ppublish

Résumé

Urinary incontinence after prostate treatment (IPT) is one of the few urologic diseases that is iatrogenic, and, therefore, predictable and perhaps preventable. Evaluation of the incontinent patient, risk factors for IPT, the assessment of the patient prior to intervention, and a stepwise approach to management are covered in this guideline. Algorithms for patient evaluation, surgical management, and device failure are also provided. This guideline was developed using a systematic review from the Mayo Clinic Evidence Based Practice Center with additional supplementation by the authors. A research librarian conducted searches from 2000 to December 21 This guideline was developed by a multi-disciplinary panel to inform clinicians on the proper assessment of patients with IPT and the safe and effective management of the condition in both surgical and non-surgical contexts. Statements guiding the clinician on proper management of device failure are also included. Most patients who undergo radical prostatectomy (RP), and some patients who undergo radiation therapy (RT) or surgery for benign prostatic hyperplasia (BPH), will experience IPT. Although non-surgical options, such as pelvic floor muscle exercises (PFME), can hasten continence recovery, patients who remain incontinent at one-year post-procedure, or have severe incontinence at six months, may elect to undergo surgical treatment (e.g. artificial urinary sphincter). Prior to IPT surgery, the risks, benefits, alternatives, and additional likely procedures should be discussed with the patient.

Identifiants

pubmed: 31059663
doi: 10.1097/JU.0000000000000314
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Pagination

369-378

Auteurs

Jaspreet S Sandhu (JS)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

Benjamin Breyer (B)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

Craig Comiter (C)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

James A Eastham (JA)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

Christopher Gomez (C)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

Daniel J Kirages (DJ)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

Chris Kittle (C)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

Alvaro Lucioni (A)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

Victor W Nitti (VW)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

John T Stoffel (JT)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

O Lenaine Westney (OL)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

M Hassan Murad (MH)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

Kurt McCammon (K)

American Urological Association Education and Research, Inc. , Linthicum , Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH